Articles

Comparing consolidation treatment with bortezomib + lenalidomide + dexamethasone (VRD) followed by lenalidomide maintenance with lenalidomide maintenance alone, the former approach was superior regarding progression-free survival (PFS) and myeloma response in patients with newly diagnosed multiple myeloma (MM) with an acceptable toxicity profile. Read More ›

This multicenter, retrospective, real-world study (GEM-POMCIDEX) was initiated to evaluate the effectiveness of the guidelines established by the Spanish Myeloma Group (PETHEMA) to treat appropriate patients with relapsed/refractory multiple myeloma (RRMM) with pomalidomide, cyclophosphamide, and dexamethasone (POMCIDEX). Read More ›

Poor response on subsequent therapies is typically seen in patients with relapsed/refractory multiple myeloma (RRMM) who have had 3 prior lines of therapy with immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies. In addition, challenges for future treatment options are presented. Read More ›

Recent studies have illustrated complete response (CR) rates >50% for transplant-eligible patients with multiple myeloma (MM) treated with optimized induction followed by high-dose therapy (HDT) and autologous stem-cell transplantation (ASCT). However, many patients relapse early. Patients who relapse are generally thought to have very low survival rates. Read More ›

According to data from the phase 2 FORTE trial, 3 different techniques were analyzed and compared to characterize minimal residual disease (MRD), including positron emission tomography/computed tomography (PET/CT), multiparameter flow cytometry (MFC), and next-generation sequencing (NGS). Read More ›

Treatment with dabrafenib and trametinib produced similar benefits in pretreated and treatment-naïve patients. Read More ›

US Food and Drug Administration–approved capmatinib is an effective second-line treatment for patients with MET exon 14–mutated NSCLC. Read More ›

First-line treatment with ramucirumab plus erlotinib in patients with EGFR-mutated metastatic NSCLC was associated with superior progression-free survival compared with erlotinib plus placebo. Read More ›

Lorlatinib is associated with longer progression-free survival and a higher overall and intracranial response rates among patients with previously untreated, advanced ALK-positive NSCLC. Read More ›

Selpercatinib and pralsetinib are US Food and Drug Administration–approved treatment options for patients with RET fusion–positive NSCLC. Read More ›